Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink
Remote patient monitoring and biosensing company will use investment to scale its OptiBP™ blood pressure measurement and monitoring product and operations worldwide; Renowned interventional cardiologist and inventor, Dr. Fred St. Goar, MD and SeedLink's Tim Juergens appointed to Biospectal's Board of Directors
- Biospectal will leverage the new funds to scale its OptiBPsmartphone blood pressure monitoring application and data platform technology worldwide.
- Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.
- OptiBP's data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life.
- SeedLink SL supports founders in successfully establishing and growing solutions in the Digital Health space, with special focus on Digital Therapeutics (DtX), Digital Biomarkers, and platform-based business models.